Philip Walden Loberg Jr. is EVP & Interim CFO at Valeant Pharmaceuticals International, Inc. (VRX). They have made 1 open-market trade across 1 company since 2011, most recently 2011-07-25.
CIK 0001508799
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $396K since 2011, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VRX | 145,065 | $3.4M |
Shares reported on the most recent Form 4, priced at the 2011-07-27 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRX | BUY | 2011-06-09 | 2011-06-13 | $52.82 | $396K | -12.8% | +0.4% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.